139 related articles for article (PubMed ID: 16217588)
1. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis.
Seeman E; Crans GG; Diez-Perez A; Pinette KV; Delmas PD
Osteoporos Int; 2006 Feb; 17(2):313-6. PubMed ID: 16217588
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
[TBL] [Abstract][Full Text] [Related]
3. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
[TBL] [Abstract][Full Text] [Related]
4. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.
Maricic M; Adachi JD; Sarkar S; Wu W; Wong M; Harper KD
Arch Intern Med; 2002 May; 162(10):1140-3. PubMed ID: 12020184
[TBL] [Abstract][Full Text] [Related]
5. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
Ettinger B; Black DM; Mitlak BH; Knickerbocker RK; Nickelsen T; Genant HK; Christiansen C; Delmas PD; Zanchetta JR; Stakkestad J; Glüer CC; Krueger K; Cohen FJ; Eckert S; Ensrud KE; Avioli LV; Lips P; Cummings SR
JAMA; 1999 Aug; 282(7):637-45. PubMed ID: 10517716
[TBL] [Abstract][Full Text] [Related]
6. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.
Delmas PD; Genant HK; Crans GG; Stock JL; Wong M; Siris E; Adachi JD
Bone; 2003 Oct; 33(4):522-32. PubMed ID: 14555255
[TBL] [Abstract][Full Text] [Related]
7. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.
Kanis JA; Johnell O; Black DM; Downs RW; Sarkar S; Fuerst T; Secrest RJ; Pavo I
Bone; 2003 Sep; 33(3):293-300. PubMed ID: 13678769
[TBL] [Abstract][Full Text] [Related]
8. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study.
Johnell O; Kanis JA; Black DM; Balogh A; Poor G; Sarkar S; Zhou C; Pavo I
J Bone Miner Res; 2004 May; 19(5):764-72. PubMed ID: 15068500
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
[TBL] [Abstract][Full Text] [Related]
10. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.
Ensrud KE; Stock JL; Barrett-Connor E; Grady D; Mosca L; Khaw KT; Zhao Q; Agnusdei D; Cauley JA
J Bone Miner Res; 2008 Jan; 23(1):112-20. PubMed ID: 17892376
[TBL] [Abstract][Full Text] [Related]
11. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
12. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
Qu Y; Wong M; Thiebaud D; Stock JL
Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
[TBL] [Abstract][Full Text] [Related]
13. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
Delmas PD; Ensrud KE; Adachi JD; Harper KD; Sarkar S; Gennari C; Reginster JY; Pols HA; Recker RR; Harris ST; Wu W; Genant HK; Black DM; Eastell R;
J Clin Endocrinol Metab; 2002 Aug; 87(8):3609-17. PubMed ID: 12161484
[TBL] [Abstract][Full Text] [Related]
15. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene: recent information on skeletal and non-skeletal effects.
Gluck O; Maricic M
Curr Opin Rheumatol; 2002 Jul; 14(4):429-32. PubMed ID: 12118180
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene and risk of vertebral fracture in postmenopausal women.
Halbekath J; Becker-Brüser W; Wille H
JAMA; 2000 May; 283(17):2236-7. PubMed ID: 10807376
[No Abstract] [Full Text] [Related]
18. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.
Lufkin EG; Whitaker MD; Nickelsen T; Argueta R; Caplan RH; Knickerbocker RK; Riggs BL
J Bone Miner Res; 1998 Nov; 13(11):1747-54. PubMed ID: 9797484
[TBL] [Abstract][Full Text] [Related]
19. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk.
Sarkar S; Reginster JY; Crans GG; Diez-Perez A; Pinette KV; Delmas PD
J Bone Miner Res; 2004 Mar; 19(3):394-401. PubMed ID: 15040827
[TBL] [Abstract][Full Text] [Related]
20. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
